Plasma medications are produced from human blood plasma (plasma). Plasma can be obtained from administration of whole blood (recovered plasma) or apheresis procedures (plasma source). The source is plasma a wide range of medicinal therapies products used for treatment and the prevention of various treatment-causing injuries and diseases often associated with a protein deficiency state. Convalescent Plasma Therapy (CP), a classic adaptive immunotherapy, has been used in the prevention and treatment of many infectious diseases for over a century. In the past two decades, CP therapy has been successfully used in the treatment of the 2009 SARS, MERS and H1N1 pandemic with satisfactory efficacy and safety. In 2014, the World Health Organization (WHO) recommended the use of convalescent plasma therapy for the treatment of patients with antibody-rich plasma in those recovering from Ebola virus disease.
Numerous clinical trials are also being held to evaluate the safety and efficacy of convalescent plasma, and the FDA has also approved a number of individual emergencies (eINDs) for emergencies.
For Better Understanding, Download Free Sample PDF Copy of Plasma Therapy Market Research Report: https://www.databridgemarketresearch.com/covid-19-resources/covid-19-impact-on-plasma-therapy-in-the-healthcare-industry
The plasma therapy manufacturers are taking much strategic decision to cope up with this current pandemic COVID-19. Global Plasma Leaders are collaborating to accelerate the development of potential COVID-19 hyperimmune therapy. Biotest, BPL, LFB and Octapharma have partnered to form an alliance formed by CSL Behring (ASKS: CSL / USOTC: CSLLI) and Takeda Pharmaceutical Company Limited (TSE: 4502 / NISE: TAK) to develop potential plasma therapy for COVID treatment-19. The alliance will begin immediately with the research development of a single, non-branded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin drug with the potential to treat individuals with serious complications of COVID-19. The collaboration will leverage the cutting edge expertise and work that companies already do. Alliance experts will begin collaborating on key aspects such as plasma collections, clinical trial development, and manufacturing.
This report presents a comprehensive overview, market shares, and growth opportunities of Plasma Therapy market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Plasma Therapy, covering the supply chain analysis, impact assessment to the Plasma Therapy market size growth rate in several scenarios, and the measures to be undertaken by Plasma Therapy companies in response to the COVID-19 epidemic.
Global Plasma Therapy Market is registering a healthy CAGR of 15.7% in the forecast period of 2019-2026.
Surging orthopedic diseases and sports injuries including arthritis, fosters the growth of the market
Growing demand for the usage of planet rich plasma for the treatment of numerous diseases, drives the growth of the market
Government initiatives for the development of plasma derived medicine, is the factor that drives the market growth
Rising awareness regarding the importance of blood donation, is the key drivers for this market
Increasing diseases including tetanus, rabies and hepatitis A&B is estimated to impact the market positively
The cost associated with plasma therapy is quite high which, is likely to impede the market growth
Absence of responsiveness regarding platelet-rich therapy, hinders the growth of the market
Absence of compensation policies and strict regulatory policies, restraint the global market growth
The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.